- SI wise, you are correct.
- Otherwise: Just think about the investment inflow $130M (could be max higher) at high premium to current price (T-2).
If this is not confidence enough Sir, I don't know what is.
We know past performance sucked due to low margin bio-fuel
and company is still in early stage commercialization.
I have to question about your strong enthusiasm as a short here, almost a ridiculous obsession. Until the final declaration of latest offering was disclosed I also held back and knew the volatility will hit. The big unknown.
Now all is set up for growth w/o liquidity issues, your ongoing bearish sentiment still gets noticed, but wiped away by the big premium investment.
Time to follow the vision again Sir.
I hope you are aware that there is a strong market for synthetic biotech companies? IMO Amyris is now better positioned than XON.
The year long experience of this company, yes - even the failures, will help making this a success story while standing on strong shoulders!